Scalper1 News
Thursday morning brought a passel of earnings reports from large-cap drugmakers, which the market greeted with a mostly unenthusiastic response. One of the most anticipated reports came from AbbVie (ABBV), which unveiled its first full quarter with hepatitis C treatment Viekira Pak and addressed questions buzzing around Wall Street about its spending strategy. AbbVie’s Q1 earnings rose 32% over the year-earlier quarter to 94 cents a share, 9 cents Scalper1 News
Scalper1 News